79 results
S-3ASR
DAWN
Day One Biopharmaceuticals, Inc.
28 Aug 24
Automatic shelf registration
4:07pm
on Response Assessment in Pediatric Neuro-Oncology Low-Grade Glioma, or RAPNO LGG.
The safety of OJEMDA was evaluated in 137 patients with relapsed … and management’s assessment of the effectiveness of internal control over financial reporting (which is included in Management’s Annual Report on Internal Control
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals, Inc.
30 Jul 24
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
7:35am
clinical trial assay Pediatric dose confirmation and efficacy assessment to begin near/at the end of adult dose escalation Initial target indications
8-K
EX-99.3
DAWN
Day One Biopharmaceuticals, Inc.
30 Jul 24
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
7:35am
, overall response rate; RAPNO, Response Assessment in Pediatric Neuro-Oncology; TTR, time to response; CR, complete response; PR, partial response; MR, minor … to be selected based on PTK7 expression clinical trial assay Pediatric dose confirmation and efficacy assessment to begin near/at the end of adult dose escalation
8-K
EX-10.1
vslr 6d8zc
30 Jul 24
Day One Announces Oversubscribed $175.0 Million Private Placement
7:04am
8-K
EX-10.2
9pmwta 9efc
30 Jul 24
Day One Announces Oversubscribed $175.0 Million Private Placement
7:04am
8-K
EX-99.1
k9j7zo0
25 Jul 24
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
6:04am
8-K
EX-99.2
yfo wmelm
18 Jun 24
Entry into a Material Definitive Agreement
8:36am
8-K
EX-99.1
2yq52dbarlvilmrjaqzk
12 Jun 24
Regulation FD Disclosure
8:07am
8-K
pwvg6wquq ut
12 Jun 24
Regulation FD Disclosure
8:07am
8-K
EX-99.2
q61kbgup0o4
30 May 24
Day One Announces Sale of Priority Review Voucher for $108 Million
8:35am
8-K
EX-99.2
2cbqe cnfb
6 May 24
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
415d lv82y
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.1
2kx1872e
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
cmv4pyc7
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
xm42m
26 Feb 24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
4:30pm